Pharmaceutical Companies Navigate Patent Expirations and Market Innovations

Pharmaceutical companies are increasingly focusing on their drug pipelines as they face significant patent expirations in the coming years. Notably, Novartis CEO Vas Narasimhan highlighted a projected loss of $4 billion in sales and profits in the first half of 2026 due to patent expirations, marking a historic low for the company. Despite these challenges, Narasimhan emphasized optimism stemming from a robust pipeline and growth drivers. Similarly, AstraZeneca is confident in its future, aiming to introduce 25 new blockbuster medicines by 2030 and increase revenue from $59 billion in 2025 to $80 billion.

CNBC

In response to the impending revenue gaps, many pharmaceutical firms are turning to mergers and acquisitions (M&A) as a strategy to replenish their drug pipelines. Companies are exploring both small acquisitions and larger late-stage deals to expedite the development of new drugs. Sanofi's recent leadership change, with Belén Garijo replacing Paul Hudson, underscores the urgency to enhance research and development productivity, particularly as Sanofi prepares for the patent expiration of its asthma drug Dupixent, which currently represents over a third of its sales.

CNBC

China has emerged as a critical source of innovation in the pharmaceutical sector. Companies are increasingly looking to collaborate with Chinese firms to access new assets and expedite clinical development processes. This shift reflects a broader trend where China is viewed not just as a market but as a platform for rapid drug development. Portfolio manager Camilla Oxhamre noted that partnerships with Chinese companies have become commonplace, contrasting sharply with the rarity of such deals a decade ago.

CNBC

The pharmaceutical industry is also grappling with pricing strategies, particularly in light of the U.S. government's Most Favored Nation drug pricing policy. Companies are contemplating whether to delay drug launches in Europe to avoid pricing constraints or adopt a single-price model, which may limit access in certain markets. AstraZeneca's CFO Aradhana Sarin emphasized the importance of developing the right pricing strategy as new medicines are launched.

CNBC

The obesity drug market, particularly for GLP-1 weight loss medications, is becoming increasingly competitive. Novo Nordisk and Eli Lilly currently dominate this space, but new entrants like AstraZeneca and Roche are developing rival treatments. Pfizer's acquisition of Metsera and Amgen's development of a once-monthly injection, MariTide, indicate a crowded market where differentiation among products is crucial.

CNBC

Pharmaceutical executives have expressed a mix of optimism and caution regarding future developments. Narasimhan stated, "We are still able to grow," while Sarin highlighted the need for a thoughtful approach to pricing strategies. The industry is actively assessing how to navigate the complexities of market dynamics and regulatory changes.

CNBC

There is uncertainty regarding the impact of pricing strategies on drug volumes, particularly in the obesity sector. Analysts have noted that price cuts do not typically lead to increased sales volumes, raising questions about consumer behavior in a direct-to-consumer market.

CNBC

• “With the scale of the patent losses that are coming up over the next few years, you probably are hearing a bigger focus on the optimism for the future, as opposed to near-term delivery,” — Vas Narasimhan, CEO of Novartis

CNBC

• “The real key, going forward, as we launch many of these new medicines, what is the right pricing strategy, and we'll have to think about that,” — Aradhana Sarin, CFO of AstraZeneca

CNBC